-+ 0.00%
-+ 0.00%
-+ 0.00%

Coherus Oncology declares CVR dividend tied to sale of remaining biosimilar assets

PUBT·08/17/2026 21:29:11
Listen to the news
Coherus Oncology declares CVR dividend tied to sale of remaining biosimilar assets
  • Coherus Oncology declared a special dividend of non-transferable contingent value rights tied to proceeds from selling remaining legacy biosimilar assets.
  • CVRs go to stockholders of record at 5 p.m. New York time on Sept. 30, 2026; distribution set for Oct. 7, 2026.
  • Payouts depend on net cash proceeds from any sale or monetization, including licensing fees; CVRs expire on Oct. 7, 2028.
  • Coherus plans to launch a sale process for the assets, supported by an investment bank adviser.
  • Disposition proceeds, CVR payments subject to restrictions under a loan agreement dated Aug. 12, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-097951), on August 17, 2026, and is solely responsible for the information contained therein.